BR112016025792A2 - meios e processos para tratamento de cmv - Google Patents

meios e processos para tratamento de cmv

Info

Publication number
BR112016025792A2
BR112016025792A2 BR112016025792A BR112016025792A BR112016025792A2 BR 112016025792 A2 BR112016025792 A2 BR 112016025792A2 BR 112016025792 A BR112016025792 A BR 112016025792A BR 112016025792 A BR112016025792 A BR 112016025792A BR 112016025792 A2 BR112016025792 A2 BR 112016025792A2
Authority
BR
Brazil
Prior art keywords
cmv
processes
treatment media
ul131a
cmv treatment
Prior art date
Application number
BR112016025792A
Other languages
English (en)
Inventor
Schaub Christian
John Corinne
Wellnitz Sabine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112016025792A2 publication Critical patent/BR112016025792A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se ao campo de produção de proteína recombinante e a preparação de vacina. em particular, a invenção provê meios e processos para a produção de complexo pentamérico de cmv de gh/gl/ul128/ul130/ul131a. mais especificamente, a invenção provê um complexo pentamérico de gh/gl/ul128/ul130/ul131a de cmv produzido em um sistema de baculovírus que pode ser usado como uma vacina contra cmv.
BR112016025792A 2014-05-08 2015-05-08 meios e processos para tratamento de cmv BR112016025792A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
LU92451 2014-05-08
LU92449 2014-05-08
LU92452 2014-05-08
LU92450 2014-05-08
PCT/IB2015/053365 WO2015170287A1 (en) 2014-05-08 2015-05-08 Means and methods for treating cmv

Publications (1)

Publication Number Publication Date
BR112016025792A2 true BR112016025792A2 (pt) 2017-10-17

Family

ID=53180768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016025792A BR112016025792A2 (pt) 2014-05-08 2015-05-08 meios e processos para tratamento de cmv

Country Status (16)

Country Link
US (1) US20150322115A1 (pt)
EP (1) EP3139953A1 (pt)
JP (1) JP2017515503A (pt)
KR (1) KR20170002560A (pt)
CN (1) CN106460010A (pt)
AU (1) AU2015257330A1 (pt)
BR (1) BR112016025792A2 (pt)
CA (1) CA2947938A1 (pt)
IL (1) IL248803A0 (pt)
MX (1) MX2016014660A (pt)
PE (1) PE20170301A1 (pt)
PH (1) PH12016502220A1 (pt)
RU (1) RU2016147987A (pt)
SG (1) SG11201608977UA (pt)
TW (1) TW201609792A (pt)
WO (1) WO2015170287A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
CA3019588A1 (en) * 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
EP3612550A1 (en) 2017-04-19 2020-02-26 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
BR112020004747A2 (pt) 2017-09-13 2020-09-24 Sanofi Pasteur composição imunogênica de citomegalovírus humano
BR112020008482A8 (pt) * 2017-11-01 2023-01-31 Merck Sharp & Dohme Composto leuco
CN108300731A (zh) * 2018-02-02 2018-07-20 暨南大学 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用
KR200492821Y1 (ko) 2018-08-10 2020-12-15 인제대학교 산학협력단 의료용 튜브 고정 기구
BR112021006812A2 (pt) 2018-10-17 2021-07-20 Glaxosmithkline Biologicals S.A. proteínas e complexos estabilizados modificados do citomegalovírus
JP7179872B2 (ja) * 2018-12-10 2022-11-29 Ｋｍバイオロジクス株式会社 サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン
CA3186423C (en) 2020-06-09 2024-03-19 Km Biologics Co., Ltd. Fusion protein of pentamer and gb of cytomegalovirus, and vaccine containing said fusion protein
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
KR102259156B1 (ko) 2020-09-28 2021-06-01 박나은 네트워크 환경 내 디바이스 인증 시스템 및 방법
AU2021367917A1 (en) 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
WO2023223255A1 (en) 2022-05-20 2023-11-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
AU783246C (en) * 1999-12-14 2007-03-15 Asahi Kasei Kabushiki Kaisha Stabilizing diluent for polypeptides and antigens
US7629160B2 (en) 2004-12-21 2009-12-08 University Of Kentucky Research Foundation Vectors and methods for enhanced cell longevity and protein expression
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
WO2007146024A2 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
WO2012034025A2 (en) * 2010-09-09 2012-03-15 Virginia Commonwealth University Human cytomegalovirus vaccine
EP3520813B1 (en) * 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
BR112013020070A8 (pt) * 2011-01-31 2019-09-03 Univ Pennsylvania moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
JP2014520807A (ja) * 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
AU2013286093B2 (en) * 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
RU2015121828A (ru) * 2012-10-30 2016-12-20 Пфайзер Инк Вакцины на основе рекомбинантных частиц против инфекции цитомегаловируса человека

Also Published As

Publication number Publication date
TW201609792A (zh) 2016-03-16
RU2016147987A (ru) 2018-06-13
EP3139953A1 (en) 2017-03-15
US20150322115A1 (en) 2015-11-12
KR20170002560A (ko) 2017-01-06
JP2017515503A (ja) 2017-06-15
MX2016014660A (es) 2017-02-28
AU2015257330A1 (en) 2016-11-17
PE20170301A1 (es) 2017-03-30
WO2015170287A1 (en) 2015-11-12
CN106460010A (zh) 2017-02-22
SG11201608977UA (en) 2016-11-29
IL248803A0 (en) 2017-01-31
CA2947938A1 (en) 2015-11-12
PH12016502220A1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
BR112016025792A2 (pt) meios e processos para tratamento de cmv
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
IL267537B (en) New converted indazoles, processes for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicines
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
EA201691582A1 (ru) Новые фармацевтические препараты
EP3151818A4 (en) Compositions and methods of treating diabetic retinopathy
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
EP3212172A4 (en) Methods and compositions particularly for treatment of attention deficit disorder
BR112017003644A2 (pt) métodos de tratamento de distúrbios do sono e para regular produção de melatonina.
ZA201703467B (en) Methods of treating ocular conditions
CL2017000367A1 (es) Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolina
EP3160233A4 (en) Reduction of infections in healthcare settings using photocatalytic compositions
EP3149035A4 (en) Therapeutic compositions including therapeutic small molecules and uses thereof
EP3106513A4 (en) Method for decomposing polyhydroxyalkanoic acid, and microorganism preparation
EP3159349A4 (en) Lobaplatin crystal, preparation method and pharmaceutical application
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MD20180049A2 (ro) Compoziţie farmaceutică
MX2017004986A (es) Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2 para terapias oculares.
EP3303345A4 (en) ERTUGLIFOZINE CO-CRYSTALS AND PROCESS FOR PREPARING THEM
백승호 Overview of drug development
IL251876A0 (en) A distillation process that includes at least two distillation steps to obtain a pure halide of a halogenated carboxylic acid and use a pure halide of a halogenated carboxylic acid
IL250705B (en) A distillation process that includes at least two stages of distillation to obtain the purified halide of a halogen-modified carboxylic acid, and the use of a purified halide of a halogen-modified carboxylic acid
TWD181173S (zh) 注射器噴嘴
UA106905U (uk) Фармацевтична композиція
TWD174081S (zh) 電連接器

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]